Investigational drug · Phase 3
BL-M07D1
Not approved by FDA. In 17 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
17
17 still active
All registered trials
21
Any phase or sponsor naming "BL-M07D1"
First trial start
2024
Jan 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL-M07D1", any sponsor or status.
- Phase 311
Conditions studied
As listed on its trial records.
- HER2-positive Breast Cancer
- Non-squamous Non-small Cell Lung Cancer
- Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
- HER2-low Breast Cancer
- Colorectal Cancer
- Breast Cancer
- Gynecological Malignancies
- Non-small Cell Lung Cancer
- Epithelial Ovarian Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Ovarian cancer · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BL-M07D1" as an intervention, largest first.
- A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyPivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06830889 · 1,450 participants (planned) · Start Jun 3, 2025 · Primary completion Oct 2031
Drug: BL-M07D1; T-DM1 · For: HER2-positive Breast Cancer
Sites: Nanjing, China; Shanghai, China
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerPivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06891833 · 985 participants (planned) · Start Jun 5, 2025 · Primary completion Dec 2028
Drug: BL-M07D1; Pertuzumab and 3 more · For: HER2-positive Breast Cancer
Sites: Bengbu, China; Hefei, China; Chongqing, China · 30 sites in all
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerPivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07518173 · 596 participants (planned) · Start Apr 21, 2026 · Primary completion Dec 2029
Drug: BL-M07D1; Pertuzumab and 2 more · For: HER2-positive Breast Cancer
Sites: Guangzhou, China; Chengdu, China
- A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerPivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06957886 · 566 participants (planned) · Start May 15, 2025 · Primary completion May 2027
Drug: BL-M07D1; Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel · For: HER2-low Breast Cancer
Sites: Guangzhou, China; Changsha, China
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyPivotal-lookingRecruiting
SystImmune Inc.Industry
NCT07869836 · 520 participants (planned) · Start Nov 2026 · Primary completion Dec 2028
Drug: T-Bren, Dose level 1; T-bren, Dose level 2 and 1 more · For: Urothelial Cancer; Metastatic Urothelial Cancer; Bladder Cancer and 9 more
Sites: Macon, Georgia; ‘Aiea, Hawaii; Fredericksburg, Virginia
- A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07152405 · 490 participants (planned) · Start Sep 24, 2025 · Primary completion Jun 2027
Drug: BL-M07D1; Investigator's choice of chemotherapy · For: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Sites: Harbin, China; Shanghai, China
- A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCPivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07178795 · 440 participants (planned) · Start Sep 29, 2025 · Primary completion Dec 2027
Drug: BL-M07D1; Pembrolizumab and 3 more · For: Non-squamous Non-small Cell Lung Cancer
Sites: Guangzhou, China
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerPivotal-lookingNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07545460 · 404 participants (planned) · Start Jul 2026 · Primary completion Dec 2028
Drug: BL-M07D1; Liposomal Doxorubicin and 2 more · For: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Beijing, China; Kunming, China
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailurePivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07606599 · 398 participants (planned) · Start Jul 7, 2026 · Primary completion Dec 2028
Drug: BL-M07D1; Oxaliplatin and 5 more · For: Biliary Tract Cancer
Sites: Hefei, China; Beijing, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05461768 · 348 participants (planned) · Start Aug 9, 2022 · Primary completion Dec 2026
Drug: BL-M07D1 · For: Breast Cancer; Locally Advanced or Metastatic Solid Tumor
Sites: Fuzhou, China; Dongguan, China; Guangdong, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours.
Yao H, Zhao R, Lai X, et al. · EBioMedicine 2026
Also in development for HER2-positive Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- DP303cPhase 34 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- A166Phase 32 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer
- ZN-A-1041ZN-A-1041 Enteric, RO7771950Phase 32 trials
Roche (Genentech) · HER2-positive Breast Cancer, Advanced Solid Tumors
- GQ1005Phase 31 trial
GeneQuantum Healthcare (Suzhou) Co., Ltd. · HER2-positive Breast Cancer
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.